AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 51 min read$DFTX

Barrow Robert sold $722K of DFTX

Barrow Robert (Chief Executive Officer) sold 19,023 shares of Definium Therapeutics, Inc. (DFTX) at $37.94 ($0.72M total) on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barrow Robert
Published Sep 5, 2026, 1:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DFTX
Neutral
high confidence
Mentioned
$DFTX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFTXNeutralLow
01

Why it matters

The transaction is a routine liquidity event with limited market impact.

02

Market read

Insider sale of ~0.7M USD is modest; unlikely to affect stock price materially.

03

What to watch

Potential upcoming clinical data could outweigh insider sale impact.

Relevance 4/10Novelty 5/10Timing: post‑market filing on Sep 4, 2026

Background

Form 4 filings disclose insider transactions; investors monitor for material changes.

Company-level read

Ticker impact

$DFTXNeutralHigh confidence
Context

CEO Barrow Robert sold 19,023 shares for $721,732 via a 10b5‑1 plan, reducing his stake to 1,494,640 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is modest relative to market cap and typical insider transactions.

Market effects

Sector

Limited; reflects routine insider liquidity in biotech sector.

Regional

None; company is US‑listed with no broader regional effect.

Global

None; isolated to Definium Therapeutics.

Counterpoint

What could challenge this read

If insider selling signals concerns, some traders may short, but evidence is weak.

Key entities

  • Person
    Barrow Robert

    Chief Executive Officer of Definium Therapeutics.

  • Company
    Definium Therapeutics, Inc.

    Biotech firm developing therapies; ticker DFTX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DFTX insider trading history →

Related articles

SEP 14
$DFTXMedAI 9/10

Definium's DT120 ODT Achieves Significant Anxiety Improvement In Phase 3 Trial; Stock Up

Definium Therapeutics (DFTX) reported positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder, meeting primary and secondary endpoints. The study showed significant reduction in HAM-A scores with a 5.1-point placebo-adjusted improvement. The company plans to submit a New Drug Application in early 2027. DFTX stock rose 3.07% to $38.89 on Friday and is up 13.40% in pre-market trading.

rttnews.com2 min
SEP 14
$DFTXHighAI 9/10

Why is Definium Therapeutics stock surging today?

Definium Therapeutics (DFTX) stock surged 20.7% in pre-market trading after its Phase 3 trial of DT120 ODT for generalized anxiety disorder met its primary endpoint. The company has also received FDA Breakthrough Therapy designation for DT120 in major depressive disorder. Analysts had previously assigned Buy or Strong Buy ratings, with price targets above current levels. The stock is nearing its 52-week high of $49.70, up from a low of $8.77.

investing.com2 min
SEP 14
$DFTXMedAI 9/10

Definium Therapeutics stock jumps on positive trial results

Definium Therapeutics (DFTX) shares rose 20% after reporting positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The study met primary and secondary endpoints, showing a 5.1-point reduction in anxiety scores. The drug was well-tolerated, with a safety profile consistent with prior trials. The company plans to file for FDA approval in 2027.

investing.com2 min